The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Agency will require a Limitation of Use section in the prescribing information of all extended-release ADHD stimulants ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...

By Andrew Silver SHANGHAI (Reuters) -Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...